Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Cancer Prevention Month: Get ACRO Health Gift Cards! Cancer Prevention Month: Get ACRO Health Gift Cards!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
FRα BsAb - 01 | PCC | Solid Tumor | Ovarian cancer,Non-small cell lung cancer |
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
FRα BsAb-ADC | Bispecific antibody | Oncology/Cancer | Ovarian cancer | Preclinical | Global |
Expression analysis of human FOLR1 on HEK293/Human FOLR1 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human FOLR1 Stable Cell Line or negative control cell using PE-labeled anti-human FOLR1 antibody.
5e5 of anti-FOLR1 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human FOLR1, His Tag (Cat. No. FO1-HP2H9) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Immobilized Anti-FOLR1 Antibody, Mouse IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus / Rhesus macaque FOLR1 Protein, His,Avitag (Cat. No. FO1-C82E8) with a linear range of 0.1-1 ng/mL (QC tested).
The purity of Mouse FOLR1 Protein, Fc Tag (Cat. No. FO1-M5254) is more than 90% and the molecular weight of this protein is around 100-125 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Folinic Acid | FTHF | Approved | Autism Spectrum Disorder; Down Syndrome; Rectal Neoplasms; Anemia; Diarrhea; Vitamin B 12 Deficiency; Colorectal Neoplasms | Details | ||||||
Mirvetuximab soravtansine | M9346-Asulfo-SPDB-DM4; IMGN-853; M9346A-sSPDB-DM4 | Approved | Immunogen Inc | Elahere | United States | Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial | Immunogen Inc | 2022-11-14 | Ovarian Neoplasms; Solid tumours; Cystadenoma, Serous; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Neoplasms; Carcinosarcoma; Adenocarcinoma | Details |
Pafolacianine Sodium | Pteroyl-L-Tyr-S0456; OTL-38; EC-17; OTL-0038 | Approved | On Target Laboratories Inc | Cytalux | United States | Ovarian Neoplasms | On Target Laboratories Inc | 2021-11-29 | Ovarian Neoplasms; Inflammatory Bowel Diseases; Arthritis, Rheumatoid; Neoplasms; Breast Neoplasms; Pituitary Neoplasms; Lung Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
4S-CAR-FRa | 4S-CAR-FRa | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms | Details |
AZD5335 | AZD5335; AZD-5335 | Phase 2 Clinical | Astrazeneca Plc | Ovarian Neoplasms; Solid tumours; Adenocarcinoma of Lung | Details |
CBP-1008 | CBP-1008 | Phase 2 Clinical | Coherent Biopharma Suzhou Co Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell | Details |
Arfolitixorin | ISO-901; 6R-MTHF | Phase 3 Clinical | Isofol Medical Ab | Rectal Neoplasms; Colonic Neoplasms; Osteosarcoma; Colorectal Neoplasms | Details |
Farletuzumab | MORAb-003 | Phase 2 Clinical | Morphotek Inc | Ovarian Neoplasms; Solid tumours; Neoplasms; Carcinoma, Ovarian Epithelial; Adenocarcinoma of Lung; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
MOv19-BBz CAR-T cells Therapy | Phase 1 Clinical | University Of Pennsylvania | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details | |
Rinatabart Sesutecan | PRO-1184 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Mesothelioma; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Luveltamab tazevibulin | STRO-002 | Phase 2 Clinical | Sutro Biopharma Inc | Solid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Endometrioid | Details |
MOv-18 IgE | MOv-18 IgE; MOv18; MOv-18 | Phase 1 Clinical | King'S College London, Cancer Research UK | Ovarian Neoplasms; Neoplasms | Details |
ITIL-306 | ITIL-306 | Phase 1 Clinical | Instil Bio Inc | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung | Details |
IMGN-151 | IMGN-151 | Phase 1 Clinical | Immunogen Inc | Ovarian Neoplasms; Cystadenocarcinoma, Serous; Breast Neoplasms; Peritoneal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Details |
AMT-151 | AMT-151 | Phase 1 Clinical | Solid tumours; Ovarian Neoplasms; Adenocarcinoma of Lung; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Mesothelioma; Adenocarcinoma, Clear Cell; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Carcinoma, Endometrioid; Adenocarcinoma | Details | |
BAT-8006 | BAT8006; BAT-8006 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
ELU-001 | ELU-001 | Phase 2 Clinical | Elucida Oncology Inc | Ovarian Neoplasms; Uterine Diseases; Carcinoma, Ovarian Epithelial; Ovarian Diseases; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Endometrioid; Neoplasm Metastasis; Adenocarcinoma | Details |
Noscapine-folate conjugate | Phase 1 Clinical | Emory University | Hematologic Neoplasms; Inflammation | Details | |
Farletuzumab ecteribulin | MORAb-202 | Phase 2 Clinical | Eisai Co Ltd, Morphotek Inc, Bristol-Myers Squibb Company | Solid tumours; Ovarian Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
UB-TT170 | UB-TT170; UB-TT-170; UB_TT170; UB_TT-170 | Phase 1 Clinical | Umoja BioPharma Inc | Osteosarcoma | Details |
This web search service is supported by Google Inc.